[{"id":"5299d983-b5a6-4139-a880-c383cdcdadb8","acronym":"SPiReL","url":"https://clinicaltrials.gov/study/NCT03349450","created_at":"2021-01-18T16:32:24.143Z","updated_at":"2025-02-25T16:07:12.338Z","phase":"Phase 2","brief_title":"DPX-Survivac and Checkpoint Inhibitor in DLBCL","source_id_and_acronym":"NCT03349450 - SPiReL","lead_sponsor":"Sunnybrook Health Sciences Centre","biomarkers":" BIRC5","pipe":" | ","alterations":" BIRC5 expression","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • maveropepimut-S (MVP-S) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 03/13/2018","start_date":" 03/13/2018","primary_txt":" Primary completion: 10/31/2021","primary_completion_date":" 10/31/2021","study_txt":" Completion: 07/18/2023","study_completion_date":" 07/18/2023","last_update_posted":"2023-11-02"},{"id":"0804d990-b4fa-44fe-9d8a-738f29afd92f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015269","created_at":"2023-08-29T16:10:06.647Z","updated_at":"2024-07-02T16:35:38.725Z","phase":"Phase 1","brief_title":"Exploratory Study on Baize DC Injection in Preventing Recurrence and Metastasis After Radical Tumor Surgery","source_id_and_acronym":"NCT06015269","lead_sponsor":"Shanghai Cell Therapy Group Co.,Ltd","biomarkers":" TP53","pipe":" | ","alterations":" TP53 expression • BIRC5 expression","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression • BIRC5 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-08-29"},{"id":"88aba52c-330f-4d12-911f-952efcb05266","acronym":"","url":"https://clinicaltrials.gov/study/NCT02851056","created_at":"2021-01-18T13:59:43.458Z","updated_at":"2024-07-02T16:36:00.560Z","phase":"Phase 1","brief_title":"Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)","source_id_and_acronym":"NCT02851056","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BIRC5","pipe":" | ","alterations":" BIRC5 expression","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 09/27/2016","start_date":" 09/27/2016","primary_txt":" Primary completion: 07/16/2018","primary_completion_date":" 07/16/2018","study_txt":" Completion: 08/09/2018","study_completion_date":" 08/09/2018","last_update_posted":"2022-11-11"},{"id":"bd30c023-8987-4b8d-8c2c-7885f1613d76","acronym":"","url":"https://clinicaltrials.gov/study/NCT04873180","created_at":"2021-05-05T11:52:34.984Z","updated_at":"2024-07-02T16:36:30.581Z","phase":"","brief_title":"Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma","source_id_and_acronym":"NCT04873180","lead_sponsor":"Sohag University","biomarkers":" BIRC5","pipe":" | ","alterations":" BIRC5 expression • BIRC5 overexpression","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression • BIRC5 overexpression"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2021-05-07"},{"id":"9ba1fa58-3a34-4e19-a5e3-b32641970e8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02123381","created_at":"2021-01-18T09:50:16.450Z","updated_at":"2024-07-02T16:36:48.334Z","phase":"Phase 2","brief_title":"Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT02123381","lead_sponsor":"Sichuan Cancer Hospital and Research Institute","biomarkers":" TP53 • BIRC5","pipe":" | ","alterations":" TP53 expression • BIRC5 expression","tags":["TP53 • BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression • BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2020-03-17"},{"id":"4344444c-75d7-40a8-8d13-8d1190b703c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00620321","created_at":"2021-01-18T02:18:20.529Z","updated_at":"2024-07-02T16:36:55.902Z","phase":"Phase 2","brief_title":"A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT00620321","lead_sponsor":"Eli Lilly and Company","biomarkers":" BIRC5","pipe":" | ","alterations":" BIRC5 expression","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • gataparsen (LY2181308)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 03/01/2008","start_date":" 03/01/2008","primary_txt":" Primary completion: 01/01/2010","primary_completion_date":" 01/01/2010","study_txt":" Completion: 01/01/2010","study_completion_date":" 01/01/2010","last_update_posted":"2019-09-09"},{"id":"d5c302f6-f239-4bba-903a-aaad67b7c5f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00129376","created_at":"2021-01-18T00:26:20.714Z","updated_at":"2024-07-02T16:36:58.407Z","phase":"Phase 2","brief_title":"Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients","source_id_and_acronym":"NCT00129376","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" BIRC5","pipe":" | ","alterations":" BIRC5 expression • BIRC5 overexpression • CDKN1B expression • TOP2A expression","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression • BIRC5 overexpression • CDKN1B expression • TOP2A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 02/01/2003","start_date":" 02/01/2003","primary_txt":" Primary completion: 07/01/2005","primary_completion_date":" 07/01/2005","study_txt":" Completion: 02/01/2010","study_completion_date":" 02/01/2010","last_update_posted":"2019-07-05"},{"id":"df9ef5ca-d318-4e93-9501-779e49ce9ce1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01764477","created_at":"2021-01-18T07:45:28.718Z","updated_at":"2024-07-02T16:37:18.793Z","phase":"Phase 1","brief_title":"Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT01764477","lead_sponsor":"Prism Pharma Co., Ltd.","biomarkers":" BIRC5 • MMP7","pipe":" | ","alterations":" BIRC5 expression","tags":["BIRC5 • MMP7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • foscenvivint (PRI724)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2017-08-17"},{"id":"5a7c5489-b239-47d8-a356-42d94714ee1a","acronym":"PRIMIER","url":"https://clinicaltrials.gov/study/NCT02413853","created_at":"2021-01-18T11:31:51.660Z","updated_at":"2024-07-02T16:37:23.393Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02413853 - PRIMIER","lead_sponsor":"University of Southern California","biomarkers":" BRAF • BIRC5","pipe":" | ","alterations":" BIRC5 expression","tags":["BRAF • BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • foscenvivint (PRI724)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 11/01/2017","primary_completion_date":" 11/01/2017","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2017-04-17"},{"id":"31ad4fb0-d303-4eae-8d17-c8dff89eabb4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01250470","created_at":"2021-01-18T05:02:20.108Z","updated_at":"2024-07-02T16:37:24.983Z","phase":"Phase 1","brief_title":"Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma","source_id_and_acronym":"NCT01250470","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IFNG","pipe":" | ","alterations":" BIRC5 expression","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 09/05/2012","start_date":" 09/05/2012","primary_txt":" Primary completion: 05/29/2014","primary_completion_date":" 05/29/2014","study_txt":" Completion: 05/29/2014","study_completion_date":" 05/29/2014","last_update_posted":"2017-02-27"}]